Literature DB >> 22358531

Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures.

H Tachibana1, J Y Kim, S Shirahata.   

Abstract

We attempted to improve antibody affinity by varying glycosylation on the light chain variable region. The human hybridoma line HB4C5 produces an antibody reactive to lung adenocarcinoma, which possess a N-glycosylated carbohydrate chain on the light chain hypervariable region. It has been shown that altering this carbohydrate structure can be accomplished by varying the level of N-acetylglucosamine in glucose free medium, a change in the carbohydrate chain could be induced which resulted in modifying antigen binding. By culturing the cells in media containing more than 20 mM N-acetylglucosamine, cells produced antibody with 10 fold improved affinity as compared with antibody produced in 20 mM glucose-containing medium. A newly induced light chain glycoform produced in the N-acetylglucosamine-containing medium was shown to be responsible for this antigen binding enhancement. Addition of glucose in the N-acetylglucosamine-containing media led to decreased antibody affinity and slightly inhibited production of a new light chain in a dose-dependent manner. Combination of 20 mM N-acetylglucosamine and 0.5 mM glucose gave a higher antibody production without the decrease of the antigen binding. These results indicate that optimization of N-glycosylation on the light chain, which leads to higher antigen binding, can be accomplished by adjusting a ratio of glucose and N-acetylglucosamine in the culture medium.

Entities:  

Year:  1997        PMID: 22358531      PMCID: PMC3449873          DOI: 10.1023/A:1007980032042

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  21 in total

1.  Canonical structures for the hypervariable regions of immunoglobulins.

Authors:  C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

2.  Recognition of IgG by Fc receptor and complement: effects of glycosidase digestion.

Authors:  N Koide; M Nose; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1977-04-25       Impact factor: 3.575

3.  Modification of oligosaccharide-lipid synthesis and protein glycosylation in glucose-deprived cells.

Authors:  S J Turco
Journal:  Arch Biochem Biophys       Date:  1980-12       Impact factor: 4.013

4.  Immunohistological characterization of human monoclonal antibody against lung cancer.

Authors:  T Yano; K Yasumoto; A Nagashima; H Murakami; S Hashizume; K Nomoto
Journal:  J Surg Oncol       Date:  1988-10       Impact factor: 3.454

5.  Glucose starvation alters lipid-linked oligosaccharide biosynthesis in Chinese hamster ovary cells.

Authors:  J I Rearick; A Chapman; S Kornfeld
Journal:  J Biol Chem       Date:  1981-06-25       Impact factor: 5.157

6.  Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains.

Authors:  H C Sox; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

7.  Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells.

Authors:  Y Kagawa; S Takasaki; J Utsumi; K Hosoi; H Shimizu; N Kochibe; A Kobata
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

8.  Serodiagnosis of cancer by using Candida cytochrome c recognized by human monoclonal antibody HB4C5.

Authors:  S Hashizume; M Kamei; K Mochizuki; S Sato; K Kuroda; M Kato; K Yasumoto; H Nakahashi; H Hirose; H Tai
Journal:  Hum Antibodies Hybridomas       Date:  1991-07

9.  Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody.

Authors:  H Tachibana; K Taniguchi; Y Ushio; K Teruya; K Osada; H Murakami
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

10.  Serodiagnosis of cancer using porcine carboxypeptidase A as an animal antigen recognized by human monoclonal antibody HB4C5.

Authors:  S Hashizume; K Mochizuki; M Kamei; K Kuroda; M Kato; S Sato; K Yasumoto; H Nakahashi; K Tsuchimoto; M Muraoka
Journal:  Hum Antibodies Hybridomas       Date:  1991-04
View more
  6 in total

1.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

2.  Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.

Authors:  Fleur S van de Bovenkamp; Ninotska I L Derksen; Pleuni Ooijevaar-de Heer; Karin A van Schie; Simone Kruithof; Magdalena A Berkowska; C Ellen van der Schoot; Hanna IJspeert; Mirjam van der Burg; Ann Gils; Lise Hafkenscheid; René E M Toes; Yoann Rombouts; Rosina Plomp; Manfred Wuhrer; S Marieke van Ham; Gestur Vidarsson; Theo Rispens
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

Review 3.  From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Diane van der Woude; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2022-05-23       Impact factor: 32.286

4.  Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems.

Authors:  M Butler
Journal:  Cytotechnology       Date:  2006-06-09       Impact factor: 2.058

5.  An Approach to Further Enhance the Cellular Productivity of Exogenous Protein Hyper-producing Chinese Hamster Ovary (CHO) Cells.

Authors:  Kiichiro Teruya; Yoshihito Daimon; Xiao-Yan Dong; Yoshinori Katakura; Takumi Miura; Akira Ichikawa; Tsukasa Fujiki; Makiko Yamashita; Tetsuya Mori; Hideya Ohashi; Sanetaka Shirahata
Journal:  Cytotechnology       Date:  2005-01       Impact factor: 2.058

6.  Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity.

Authors:  Olivier M Lardinois; Leesa J Deterding; Jacob J Hess; Caroline J Poulton; Candace D Henderson; J Charles Jennette; Patrick H Nachman; Ronald J Falk
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.